trending Market Intelligence /marketintelligence/en/news-insights/trending/CGDD8y448paYaSUuOz5D8Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Israel's Kitov acquires FameWave in $10M stock deal

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Israel's Kitov acquires FameWave in $10M stock deal

Kitov Pharma Ltd. acquired biopharmaceutical company FameWave Ltd. for $10 million in newly issued American depositary shares priced at $1.23 apiece along with a 50% warrant coverage.

The warrants have an exercise price of $1.98 per ADS with a four-year term.

As part of the deal, OrbiMed Advisors LLC, Pontifax Ltd. and Arkin Holdings, which collectively hold about 90% of FameWave, are exchanging their shares in FameWave for Kitov ADSs and warrants and investing $3.5 million in Kitov in exchange for additional newly issued ADSs of Kitov. The three companies will now each hold a stake of about 11% in Kitov.

The Tel Aviv, Israel-based pharmaceutical company will also acquire FameWave's cancer drug CM-24. Kitov in the second half of 2020 plans to evaluate CM-24 in combination with Bristol-Myers Squibb Co.'s Opdivo in an early-stage study for treating non-small cell lung cancer.